Developer docs
API playgroundTry for free, no card

Search company profiles

AllRock Bio

Full company profile

uuid00003ig

Namestring
AllRock Bio
Legal namestring
Allrock Bio, Inc.
Websiteurl
allrockbio.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

AllRock Bio is a privately held, clinical-stage biotechnology company founded in April 2024 and based in Natick, Massachusetts, focused on developing therapies for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH). The company's lead product candidate, ROC-101, is a first-in-class, orally administered pan-Rho-associated protein kinase (pan-ROCK) inhibitor exclusively licensed from Sanofi that selectively and potently inhibits both ROCK1 and ROCK2 isoforms, producing anti-proliferative, anti-inflammatory, and anti-fibrotic effects. ROC-101 completed a Phase 1 trial in 92 healthy volunteers demonstrating safety, no hypotension up to 40 mg once-daily, dose-dependent target engagement, and greater than 20 times the exposure of fasudil, and is now being evaluated in the open-label Phase 2a ROCSTAR trial (NCT07175038) enrolling up to 30 PAH and 10 ILD-PH patients in combination with standard of care including sotatercept, with pulmonary vascular resistance at week 24 as the primary endpoint.

The company operates as a spin-out from JucaBio under a hub-and-spoke model and is led by a team of repeat biotech entrepreneurs, most notably CEO Catherine Pearce and CBO Justin Thompson, who previously built CinCor Pharma through its acquisition by AstraZeneca for up to $1.8 billion in early 2023. The broader executive bench, including the CMO, CTMO, CFO, and heads of clinical operations, regulatory, and quality, draws heavily from the same CinCor alumni network, supplemented by experienced operators from Merck, Alexion, Keros Therapeutics, and other biopharma organizations. AllRock closed a $50 million Series A in September 2025 co-led by Versant Ventures and Westlake BioPartners to fund Phase 2a development.

AllRock is pre-revenue and its business model is centered on advancing ROC-101 through clinical development to FDA approval, at which point it intends to commercialize through traditional pharmaceutical channels targeting pulmonologists and specialized treatment centers, including specialty pharmacies, hospital pharmacies, and specialty distributors. Pricing has not yet been determined and will be set at launch in line with US specialty pharmaceutical benchmarks for orphan or rare cardiopulmonary indications. The underlying revenue mechanic is prescription drug sales of a single oral small-molecule asset across two indications with significant unmet need: PAH (approximately 57% five-year survival despite 16 approved drugs) and ILD-PH (approximately 38% five-year survival with very limited treatment options).

Short descriptiontext

AllRock Bio is a clinical-stage biotechnology company developing ROC-101, a first-in-class oral pan-ROCK inhibitor for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, with the asset licensed from Sanofi and advancing through a Phase 2a trial.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNatick, United States
HQ citystring
Natick
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pulmonary hypertension therapeutics, pan-ROCK inhibitor drugs, cardiopulmonary drug development, interstitial lung disease treatment, fibrotic disease therapies
Industry3 codes
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pulmonary Hypertension Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Once approved, AllRock Bio will generate revenue through the sale of ROC-101 for the treatment of PAH and ILD-PH. As a clinical-stage biotechnology company developing a novel therapeutic, revenue will come from prescription drug sales through traditional pharmaceutical commercialization channels.

allrockbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AllRock Bio is a clinical-stage biotechnology company developing ROC-101, a first-in-class oral pan-Rho-associated protein kinase (ROCK) inhibitor that selectively targets both ROCK1 and ROCK2 isoforms. The company is advancing ROC-101 through Phase 2a clinical trials (ROCSTAR) for the treatment of Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension associated with Interstitial Lung Disease (ILD-PH), with potential for once-daily oral dosing in combination with standard of care including sotatercept.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1 demonstrated ROC-101 was safe, well-tolerated at all doses tested up to 40mg once daily with no evidence of hypotension
+2 more records
Product overview1 text field

AllRock Bio is a clinical-stage biotechnology company developing ROC-101 as its lead product candidate. ROC-101 is a first-in-class, oral pan-ROCK inhibitor being advanced through clinical development for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH). The company operates as a spin-off from JucaBio, leveraging expertise from previous biotech ventures including CinCor Pharma (acquired by AstraZeneca for up to $1.8 billion in 2023).

Product and service1 record
1ROC-101
CategoryPulmonary hypertension therapeutics / pan-ROCK inhibitor
Description

ROC-101 is a first-in-class, oral pan-Rho-associated protein kinase (ROCK) inhibitor that selectively and potently inhibits both ROCK1 and ROCK2 isoforms. It targets anti-proliferative, anti-inflammatory, and anti-fibrotic mechanisms for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH), with favorable pharmacokinetics supporting once-daily dosing and no evidence of hypotension at doses up to 40mg.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

AllRock Bio exclusively licensed ROC-101 from Sanofi. The pan-ROCK inhibitor was acquired by AllRock to advance through Phase 2 clinical development for PAH and ILD-PH.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

JucaBio is the parent company and founder of AllRock Bio. JucaBio is a privately held, clinical-stage biopharmaceutical company built on the hub-and-spoke model that acquires high-quality, differentiated assets and builds agile NewCos. Leadership team members including Catherine Pearce and Justin Thompson co-founded JucaBio.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Developed sotatercept (Winrevair), the new standard-of-care backbone in PAH that AllRock's ROC-101 is being combined with; the strategic anchor whose commercial trajectory directly drives ROC-101 adoption.

TypeDirect peer
Description

Late-stage PAH-focused biotech developing levosimendan (TNX-101, TNX-103); overlaps with AllRock on PAH patient population, clinical-stage risk profile, and specialty cardiology/pulmonology channels.

TypeDirect peer
Description

Commercializes YUTREPIA (inhaled treprostinil) for PAH and PH-ILD; directly overlaps with AllRock's ILD-PH patient population and competes in the same specialty pharmacy channel.

TypeDirect peer
Description

Develops brensocatib and is expanding into pulmonary hypertension; a clinical-stage respiratory biotech pursuing similar specialty pulmonology channels and PAH/ILD indications.

TypeDirect peer
Description

Develops cibotercept (KERO-006), an activin receptor type IIB ligand trap for PAH that mechanistically follows sotatercept; directly comparable as a late-stage PAH biologic competitor and potential combination partner for AllRock's add-on strategy.

TypeDirect peer
Description

Developed inhaled imatinib for PH-ILD; direct precedent for a clinical-stage PAH/PH-ILD asset and a useful comparable for valuation and strategic outcomes in the indication.

TypeEmerging player
Description

Develops L-arginine formulations for PAH; overlaps with AllRock on PAH mechanism innovation and represents another clinical-stage entrant in the broader PAH development landscape.

TypeEmerging player
Description

Clinical-stage company developing rodatristat ethyl and other assets for PAH and rare respiratory diseases; comparable as a small, indication-focused PAH biotech targeting similar specialist prescribers.

TypeBroad incumbent
Description

Largest dedicated PAH franchise (Tyvaso, Remodulin, Orenitram); serves the same PAH specialists and treatment centers and sets the standard-of-care against which ROC-101 will be combined.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing seralutinib for PAH (TYvaso/LTyP-A studies); competes head-to-head with AllRock for the same PAH specialists and treatment paradigm, also targeting vascular remodeling.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AllRock Bio

Pulmonary Hypertension Therapeuticsallrockbio.com

AllRock Bio is a clinical-stage biotechnology company developing ROC-101, a first-in-class oral pan-ROCK inhibitor for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, with the asset licensed from Sanofi and advancing through a Phase 2a trial.

What AllRock Bio does

AllRock Bio is a privately held, clinical-stage biotechnology company founded in April 2024 and based in Natick, Massachusetts, focused on developing therapies for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH). The company's lead product candidate, ROC-101, is a first-in-class, orally administered pan-Rho-associated protein kinase (pan-ROCK) inhibitor exclusively licensed from Sanofi that selectively and potently inhibits both ROCK1 and ROCK2 isoforms, producing anti-proliferative, anti-inflammatory, and anti-fibrotic effects. ROC-101 completed a Phase 1 trial in 92 healthy volunteers demonstrating safety, no hypotension up to 40 mg once-daily, dose-dependent target engagement, and greater than 20 times the exposure of fasudil, and is now being evaluated in the open-label Phase 2a ROCSTAR trial (NCT07175038) enrolling up to 30 PAH and 10 ILD-PH patients in combination with standard of care including sotatercept, with pulmonary vascular resistance at week 24 as the primary endpoint.

The company operates as a spin-out from JucaBio under a hub-and-spoke model and is led by a team of repeat biotech entrepreneurs, most notably CEO Catherine Pearce and CBO Justin Thompson, who previously built CinCor Pharma through its acquisition by AstraZeneca for up to $1.8 billion in early 2023. The broader executive bench, including the CMO, CTMO, CFO, and heads of clinical operations, regulatory, and quality, draws heavily from the same CinCor alumni network, supplemented by experienced operators from Merck, Alexion, Keros Therapeutics, and other biopharma organizations. AllRock closed a $50 million Series A in September 2025 co-led by Versant Ventures and Westlake BioPartners to fund Phase 2a development.

AllRock is pre-revenue and its business model is centered on advancing ROC-101 through clinical development to FDA approval, at which point it intends to commercialize through traditional pharmaceutical channels targeting pulmonologists and specialized treatment centers, including specialty pharmacies, hospital pharmacies, and specialty distributors. Pricing has not yet been determined and will be set at launch in line with US specialty pharmaceutical benchmarks for orphan or rare cardiopulmonary indications. The underlying revenue mechanic is prescription drug sales of a single oral small-molecule asset across two indications with significant unmet need: PAH (approximately 57% five-year survival despite 16 approved drugs) and ILD-PH (approximately 38% five-year survival with very limited treatment options).

AllRock Bio firmographics

Firmographics
Name
AllRock Bio
Legal name
Allrock Bio, Inc.
Website
https://allrockbio.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
AllRock Bio is a clinical-stage biotechnology company developing ROC-101, a first-in-class oral pan-ROCK inhibitor for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, with the asset licensed from Sanofi and advancing through a Phase 2a trial.
Ownership category
akta.pro rank

AllRock Bio industry classification

Industry
Product category
Pulmonary Hypertension Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Pulmonary hypertension therapeutics
  • Pan-ROCK inhibitor drugs
  • Cardiopulmonary drug development
  • Interstitial lung disease treatment
  • Fibrotic disease therapies

Where AllRock Bio is headquartered

Location

Headquarters

HQ city
Natick
HQ country
United States
HQ region
North America

Offices1 record

Markets served

AllRock Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Revenue: Once approved, AllRock Bio will generate revenue through the sale of ROC-101 for the treatment of PAH and ILD-PH. As a clinical-stage biotechnology company developing a novel therapeutic, revenue will come from prescription drug sales through traditional pharmaceutical commercialization channels.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

AllRock Bio product offering

Product offering

Core offering

AllRock Bio is a clinical-stage biotechnology company developing ROC-101, a first-in-class oral pan-Rho-associated protein kinase (ROCK) inhibitor that selectively targets both ROCK1 and ROCK2 isoforms. The company is advancing ROC-101 through Phase 2a clinical trials (ROCSTAR) for the treatment of Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension associated with Interstitial Lung Disease (ILD-PH), with potential for once-daily oral dosing in combination with standard of care including sotatercept.

Product overview

AllRock Bio is a clinical-stage biotechnology company developing ROC-101 as its lead product candidate. ROC-101 is a first-in-class, oral pan-ROCK inhibitor being advanced through clinical development for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH). The company operates as a spin-off from JucaBio, leveraging expertise from previous biotech ventures including CinCor Pharma (acquired by AstraZeneca for up to $1.8 billion in 2023).

Differentiator

Problem solved

Functional benefit

Products and services

  • ROC-101 ROC-101 is a first-in-class, oral pan-Rho-associated protein kinase (ROCK) inhibitor that selectively and potently inhibits both ROCK1 and ROCK2 isoforms. It targets anti-proliferative, anti-inflammatory, and anti-fibrotic mechanisms for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH), with favorable pharmacokinetics supporting once-daily dosing and no evidence of hypotension at doses up to 40mg.

Quantifiable outcome

  • Phase 1 demonstrated ROC-101 was safe, well-tolerated at all doses tested up to 40mg once daily with no evidence of hypotension
  • +2 more outcomes

Companies that use AllRock Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

AllRock Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

AllRock Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • SanoficoreOEM/ Whitelabel/ Licensing PartnerAllRock Bio exclusively licensed ROC-101 from Sanofi. The pan-ROCK inhibitor was acquired by AllRock to advance through Phase 2 clinical development for PAH and ILD-PH.
  • JucaBiocoreStrategic or Co-development PartnerJucaBio is the parent company and founder of AllRock Bio. JucaBio is a privately held, clinical-stage biopharmaceutical company built on the hub-and-spoke model that acquires high-quality, differentiated assets and builds agile NewCos. Leadership team members including Catherine Pearce and Justin Thompson co-founded JucaBio.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

AllRock Bio competitors and assessment

Company assessment

Broad incumbents

  • Acceleron Pharma (a Merck company): Developed sotatercept (Winrevair), the new standard-of-care backbone in PAH that AllRock's ROC-101 is being combined with; the strategic anchor whose commercial trajectory directly drives ROC-101 adoption.
  • United Therapeutics: Largest dedicated PAH franchise (Tyvaso, Remodulin, Orenitram); serves the same PAH specialists and treatment centers and sets the standard-of-care against which ROC-101 will be combined.

Direct peers

  • Tenax Therapeutics: Late-stage PAH-focused biotech developing levosimendan (TNX-101, TNX-103); overlaps with AllRock on PAH patient population, clinical-stage risk profile, and specialty cardiology/pulmonology channels.
  • Liquidia Corporation: Commercializes YUTREPIA (inhaled treprostinil) for PAH and PH-ILD; directly overlaps with AllRock's ILD-PH patient population and competes in the same specialty pharmacy channel.
  • Insmed: Develops brensocatib and is expanding into pulmonary hypertension; a clinical-stage respiratory biotech pursuing similar specialty pulmonology channels and PAH/ILD indications.
  • Keros Therapeutics: Develops cibotercept (KERO-006), an activin receptor type IIB ligand trap for PAH that mechanistically follows sotatercept; directly comparable as a late-stage PAH biologic competitor and potential combination partner for AllRock's add-on strategy.
  • Aerovate Therapeutics: Developed inhaled imatinib for PH-ILD; direct precedent for a clinical-stage PAH/PH-ILD asset and a useful comparable for valuation and strategic outcomes in the indication.
  • Gossamer Bio: Clinical-stage biopharmaceutical company developing seralutinib for PAH (TYvaso/LTyP-A studies); competes head-to-head with AllRock for the same PAH specialists and treatment paradigm, also targeting vascular remodeling.

Emerging players

  • Pharmosa BioPharm: Develops L-arginine formulations for PAH; overlaps with AllRock on PAH mechanism innovation and represents another clinical-stage entrant in the broader PAH development landscape.
  • Altavant Sciences: Clinical-stage company developing rodatristat ethyl and other assets for PAH and rare respiratory diseases; comparable as a small, indication-focused PAH biotech targeting similar specialist prescribers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

AllRock Bio social profiles

Digital presence

AllRock Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AllRock Bio leadership team

Management profile

Number of profiles

Profiles10 records

AllRock Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AllRock Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AllRock Bio

What does AllRock Bio do?

AllRock Bio is a clinical-stage biotechnology company developing ROC-101, a first-in-class oral pan-Rho-associated protein kinase (ROCK) inhibitor that selectively targets both ROCK1 and ROCK2 isoforms. The company is advancing ROC-101 through Phase 2a clinical trials (ROCSTAR) for the treatment of Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension associated with Interstitial Lung Disease (ILD-PH), with potential for once-daily oral dosing in combination with standard of care including sotatercept.

Is AllRock Bio a public or private company?

AllRock Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was AllRock Bio founded?

AllRock Bio was founded in 2024. It employs 11 to 50 people.

Where is AllRock Bio based?

AllRock Bio is headquartered in Natick, United States, in the North America region.

How does AllRock Bio make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are AllRock Bio's main competitors?

Broad incumbents on record are Acceleron Pharma (a Merck company) and United Therapeutics. Direct peers are Tenax Therapeutics, Liquidia Corporation, Insmed, Keros Therapeutics, Aerovate Therapeutics and Gossamer Bio. Emerging players are Pharmosa BioPharm and Altavant Sciences.

Does AllRock Bio have an API?

No public API is recorded for AllRock Bio.

What industry is AllRock Bio in?

AllRock Bio's product category is Pulmonary Hypertension Therapeutics. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Clinical Trials ArenaAllRock Bio begins patient dosing in Phase IIa ROCSTAR trialAllRock Bio dosed the first patients in its Phase IIa ROCSTAR trial for ROC-101, an oral pan-ROCK inhibitor for pulmonary hypertension. The trial will assess tolerability, efficacy, and safety in up to 30 PAH and 10 ILD-PH patients, with the primary endpoint being change in pulmonary vascular resistance at week 24.PR NewswireAllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary HypertensionAllRock Bio has announced the dosing of the first patients in its Phase 2a ROCSTAR trial evaluating ROC-101, a first-in-class oral pan-ROCK inhibitor, in patients with pulmonary arterial hypertension (PAH) or PH associated with interstitial lung disease (ILD-PH). The open-label, multicenter study will enroll up to 30 PAH and 10 ILD-PH patients to evaluate safety, tolerability, and efficacy, with the primary endpoint measuring change in pulmonary vascular resistance at week 24. The trial is designed to assess ROC-101 in combination with standard of care therapies, including a dedicated arm for patients on sotatercept, building on favorable Phase 1 safety data.Pulse 2.0AllRock Bio: $50 Million Series A Raised For Advancing Lead Clinical Program For Pulmonary HypertensionAllRock Bio raised $50 million in a Series A led by Versant Ventures and Westlake BioPartners to advance its lead drug ROC-101 into Phase 2 trials for pulmonary hypertension. The oral pan-ROCK inhibitor targets PAH and ILD-PH, with enrollment expected to begin in late 2025.citybizVersant Ventures Co-led $50M Series A For AllRock BioAllRock Bio raised $50 million in a Series A co-led by Versant Ventures and Westlake BioPartners. Proceeds will advance its lead molecule ROC-101, a pan-ROCK inhibitor, into Phase 2 clinical development for pulmonary arterial hypertension and ILD-PH. The Phase 2a ROCSTAR trial is expected to start in late 2025.citybizWestlake BioPartners Co-led $50M Series A For AllRock BioAllRock Bio raised $50 million in a Series A round co-led by Versant Ventures and Westlake BioPartners. The funds will advance its lead molecule ROC-101, a pan-ROCK inhibitor, into Phase 2a trials for PAH and ILD-PH. The company's Phase 1 data showed favorable safety and tolerability.BioSpaceAllRock Bio Announces $50 Million Series A to Advance Lead Clinical Program for Pulmonary HypertensionAllRock Bio raised $50 million in a Series A co-led by Versant Ventures and Westlake BioPartners to advance its lead molecule ROC-101 into Phase 2a clinical trials for pulmonary arterial hypertension and ILD-PH. The company's Phase 2a ROCSTAR trial is expected to start in late 2025, following favorable Phase 1 safety data.AllrockbioAllRock Bio Announces $50 Million Series A to Advance Lead Clinical Program for Pulmonary Hypertension • Allrock BioAllRock Bio raised $50 million in a Series A co-led by Versant Ventures and Westlake BioPartners to advance its lead molecule ROC-101, a pan-ROCK inhibitor, into Phase 2a clinical trials for pulmonary arterial hypertension and ILD-PH. The company's Phase 1 data showed favorable safety and tolerability, and the Phase 2a trial is expected to start in late 2025.VC News DailyAllRock Bio Announces $50M Series A RoundAllRock Bio announced a $50 million Series A round co-led by Versant Ventures and Westlake BioPartners. Proceeds will advance its lead molecule ROC-101, a pan-ROCK inhibitor, into Phase 2 clinical development for pulmonary arterial hypertension and fibrotic diseases.PR NewswireAllRock Bio Announces $50 Million Series A to Advance Lead Clinical Program for Pulmonary HypertensionAllRock Bio raised $50 million in a Series A co-led by Versant Ventures and Westlake BioPartners to advance its lead molecule ROC-101 into Phase 2a clinical trials for pulmonary arterial hypertension and ILD-PH. The company's Phase 1 data showed favorable safety and tolerability, and the Phase 2a trial is expected to start in late 2025.VenturecapitalAllRock Bio Inc. Raises $50M to Advance Innovative Therapy for Cardiopulmonary DiseasesAllRock Bio Inc. has secured a $50 million Series A round of funding to advance its pan-ROCK inhibitor therapy ROC-101 into Phase 2 clinical development for pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (ILD-PH). The funding will support clinical trials for the treatment of these cardiopulmonary conditions using an AI-assisted discovery approach.